NCT01237236View on ClinicalTrials.gov

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.

PHASE1CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

December 21, 2010

Primary Completion Date

March 9, 2017

Study Completion Date

March 9, 2017

Conditions
Advanced Solid TumorLymphomas
Interventions
DRUG

LEE011

Trial Locations (7)

10017

Memorial Sloan Kettering MSKCC (2), New York

37203

Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2), Nashville

69373

Novartis Investigative Site, Lyon

94805

Novartis Investigative Site, Villejuif

02215

Dana Farber Cancer Institute DFCI, Boston

+1 48109 0944

University of Michigan Comprehensive Cancer Center SC, Ann Arbor

3584CX

Novartis Investigative Site, Utrecht

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY